Distributes medicines, healthcare products and related services to healthcare providers and pharmaceutical manufacturers.
10-K for FY2025, filed Nov 25, 2025
Cencora earns most of its revenue by distributing pharmaceuticals and related products: customers pay when ownership passes to them. Service fees are earned over the period services are provided, while manufacturer fees are earned as the service is performed.
10-K for FY2025, filed Nov 25, 2025The Company’s revenues are primarily generated from the distribution of pharmaceutical products. The Company also generates revenues from…View ↗
The Company recognizes revenue related to the distribution of products at a point in time when title and control transfers to customers and…View ↗
When the Company is the agent in a transaction, the fee received from a manufacturer customer is recognized within revenue as the service…View ↗
$321.3B
10-K for FY2025, filed Nov 25, 2025
$321.3B ↗| Segment | Share | Revenue | How money arrives |
|---|---|---|---|
|
U.S. Healthcare Solutions
Sold outright
10-K for FY2025, filed Nov 25, 2025 |
89%
FY2022: 89%
|
U.S. Healthcare Solutions, FY2025
$285B Sources
|
Sold outright |
|
International Healthcare Solutions
|
8.8%
FY2022: 11%
|
International Healthcare Solutions, FY2025
$28.3B Sources
|
Healthcare providers—including hospitals, pharmacies, clinics, physicians and veterinarians—and pharmaceutical manufacturers buy Cencora's products and services; it is typically the primary supplier to provider customers.
10-K for FY2025, filed Nov 25, 2025
10-K for FY2025, filed Nov 25, 2025
We continually seek to strengthen our existing customer relationships and seek new customers to enhance our revenues, results of…View ↗
Yes. It kept less than a cent of every revenue dollar as net income in FY2025 and turned 1 cent into free cash flow.
10-Q for Q3 FY2026, filed Aug 5, 2026
$763.5MView ↗
10-Q for Q3 FY2026, filed Aug 5, 2026
Open tableView ↗
8-K, filed May 29, 2026
On May 27, 2026, Cencora, Inc. (the “Company”) announced that Eva C. Boratto has been appointed Executive Vice President and Chief…View ↗
8-K, filed Mar 23, 2026
CONSHOHOCKEN, PA, March 23, 2026 — Cencora, Inc. (NYSE: COR) today announced the signing of a definitive agreement to acquire EyeSouth…View ↗
Growing. Revenue grew 50% in 4 years, from $214B in FY2021 to $321.3B in FY2025, about 11% a year.
Expanded international life-sciences services
The latest report describes regulatory, market-access, drug-safety, development and quality services as part of International Healthcare Solutions; the older report described these PharmaLex services as part of a planned acquisition.
10-K for FY2022, filed Nov 22, 2022 10-K for FY2025, filed Nov 25, 2025In September 2022, we entered into a definitive agreement to acquire PharmaLex Holding GmbH (“PharmaLex”), a leading provider of…View ↗
The International Healthcare Solutions reportable segment consists of businesses that focus on international pharmaceutical wholesale and…View ↗
Competes with McKesson, Cardinal Health, and UPS Logistics
10-K for FY2025, filed Nov 25, 2025We operate in a highly competitive global environment in the distribution of pharmaceuticals and related healthcare services. Our largest…View ↗
Loading...